Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111S: 154203.
[http://dx.doi.org/10.1016/j.metabol.2020.154203] [PMID: 32151660]

Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 2016; 17(14): 1937-46.
[http://dx.doi.org/10.1080/14656566.2016.1225727] [PMID: 27564402]

Polyzos SA, Kechagias S, Tsochatzis E. Review article: non-alcoholic fatty liver disease and cardiovascular diseases - associations and treatment considerations. Aliment Pharmacol Ther 2021; 54(8): 1013-25.
[http://dx.doi.org/10.1111/apt.16575]

Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res 2021; 52(1): 25-37.
[http://dx.doi.org/10.1016/j.arcmed.2020.11.0; 54(8): 1013-25.10] [PMID: 33334622]

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328-57.
[http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]

Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.
[http://dx.doi.org/10.1016/j.metabol.2018.11.014] [PMID: 30502373]

Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375(7): 631-43.
[http://dx.doi.org/10.1056/NEJMoa1509840] [PMID: 27532829]

Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 2020; 104: 154144.
[http://dx.doi.org/10.1016/j.metabol.2020.154144] [PMID: 31930974]

Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019; 394(10215): 2184-96.
[http://dx.doi.org/10.1016/S0140-6736(19)33041-7] [PMID: 31813633]

Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol 2019; 863: 172661.
[http://dx.doi.org/10.1016/j.ejphar.2019.172661] [PMID: 31536725]

Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 2020; 72(1): 58-71.
[http://dx.doi.org/10.1002/hep.31205] [PMID: 32115759]

Schwabl P, Hambruch E, Budas GR, et al. The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model. Biomedicines 2021; 9(1): 60.
[http://dx.doi.org/10.3390/biomedicines9010060] [PMID: 33435509]

Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 2021; 73(2): 625-43.
[http://dx.doi.org/10.1002/hep.31622] [PMID: 33169409]

Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384(12): 1113-24.
[http://dx.doi.org/10.1056/NEJMoa2028395] [PMID: 33185364]

Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012; 46(4): 272-84.
[http://dx.doi.org/10.1097/MCG.0b013e31824587e0] [PMID: 22395062]